Novel dry eye treatment shows efficacy in phase 2 trial
Click Here to Manage Email Alerts
ST-100, a novel dry eye treatment, achieved positive topline results in a phase 2 clinical trial, according to a press release from Stuart Therapeutics.
In the multicenter, randomized, controlled, double-masked trial, 160 patients received twice-daily dosing of 20 mg/mL of ST-100, 50 mg/mL of ST-100 or placebo.
The 50 mg/mL group achieved the study’s primary endpoint of Schirmer’s test responder rate at 28 days (P = .0266). The therapy also demonstrated improvement in several symptoms and ocular staining scores as early as day 7, as well as improvement in overall ocular discomfort at day 14 (P = .0332).
The treatment was well tolerated, and no serious drug-related adverse events were observed during the trial.
“The phase 2 trial has provided us with an important understanding of the efficacy and tolerability of ST-100 as a topical ophthalmic therapeutic and provided us with a wealth of human data to further explore the details of the mechanism of action and the potential for ST-100 and our collagen mimetic platform technology, PolyCol, in additional disease indications,” Eric Schlump, president and CEO of Stuart, said in the release.
Read more about
Click Here to Manage Email Alerts